Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2/3
Started
2022-12-20
Last updated
2026-04-06
Condition(s) studied
SSTR Positive Tumors
Investigational drug(s) / intervention(s)
Al18F-octreotide
Al18F-octreotide: Al18F-octreotide I was injected into the patients before the PET/CT scans
Study summary
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with suspected or clearly diagnosed SSTR positive tumors
* signed written consent.
* Willing and able to cooperate with all projects in this study.
Exclusion Criteria:
* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Primary outcome measure(s)
Diagnostic value — through study completion, an average of 1 year] Sensitivity and Specificity of Al18F-octreotide PET/CT for SSTR positive tumors
Trial sites (1)
Facility
City
Region
Status
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing
Chao Yang
Recruiting
More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.